Cogent Biosciences, Inc.
COGTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Valued at $5.42B, COGT is a mid-cap name in its sector. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Market Cap
$5.42B
Beta
0.31
P/E (TTM)
—
P/E (Fwd)
-26.08
EPS (TTM)
$-2.16
EPS (Fwd)
$-1.20
ROE
-109.7%
ROA
-43.8%
Cash
$792.3M
Total Debt
$244.3M
Free CF
-$186.1M
52W Change
92.7%
Annual Financials
Cash vs Debt
Where COGT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, COGT finished 15.32% below its 150-day moving average ($35.44) and 16.36% below its 200-day moving average ($35.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is COGT overbought or oversold?
At the October 20, 2026 close, COGT's RSI(14) was 39.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cogent Biosciences, Inc. holds $792.3M in cash against $244.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$186.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -109.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Cogent Biosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, COGT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing COGT.